TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

(marketscreener.com) WALTHAM, Mass., Oct. 05, 2022 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor engineered T cell therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts at the upcoming Society for Immunotherapy of Cancer 37th Annual Meeting,...https://www.marketscreener.com/quote/stock/TSCAN-THERAPEUTICS-INC-124803355/news/TScan-Therapeutics-Announces-Upcoming-Poster-Presentations-at-the-37th-Society-for-Immunotherapy-of-41933311/?utm_medium=RSS&utm_content=20221005